Log In Sign up
The largest database of trusted experimental protocols

Xenogen ivis lumina 2 system

Manufactured by PerkinElmer
Visit Supplier
Sourced in United States

The Xenogen IVIS Lumina II system is a laboratory imaging device designed to capture and analyze bioluminescent and fluorescent signals from biological samples. The system utilizes a highly sensitive charge-coupled device (CCD) camera to detect and quantify light emissions from cells, tissues, or organisms that have been engineered to express reporter genes. The core function of the IVIS Lumina II is to provide non-invasive, real-time monitoring and analysis of biological processes within living subjects.

Automatically generated - may contain errors

Lab products found in correlation

Odyssey nir fluorescence imaging instrument, by LI COR (1 mentions) C57bl 6j wt mice, by Jackson ImmunoResearch (1 mentions) Ccd camera, by PerkinElmer (1 mentions)

Close spelling variants of this product

Xenogen IVIS Lumina system Xenogen IVIS lumina II Xenogen IVIS Lumina IVIS Lumina II system Xenogen Lumina II Xenogen IVIS system IVIS Lumina system IVIS Lumina II Xenogen IVIS IVIS Lumina

5 protocols using xenogen ivis lumina 2 system

1

In Vivo Bioluminescence Imaging Protocol

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
BLI was performed using the Xenogen IVIS Lumina II system (Perkin Elmer, Waltham, MA, USA) as detailed previously [28 (link), 29 (link)].
Jia X.H., Feng G.W., Wang Z.L., Du Y., Shen C., Hui H., Peng D., Li Z.J., Kong D.L, & Tian J. (2016). Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects. Oncotarget, 7(15), 20934-20944.
+ Open protocol
+ Expand
2

Biodistribution and Pharmacokinetics of NP-siRNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were conducted in accordance with University of Washington Institutional Animal Care and Use Committee (IACUC) approved protocols (IACUC 3441-05) as well as with federal guidelines. C57BL/6J WT mice (Jackson Laboratories) were systemically administrated via tail vein injection with Dy677 labeled NP-siScrambled-CTX (NP-siScr-Dy677-CTX as a siRNA control NP). The non-injected animal was included in the study as control. Two and or forty-eight hours after injection, the mice were euthanized and tissues were dissected from brain, liver, kidneys and spleen. Each tissue was imaged using a Xenogen IVIS Lumina II system (Perkin Elmer) to examine NP distribution.
Blood was collected by retro-orbital eye bleed or terminal heart puncture for blood half-life evaluation at 0.5, 1, 2, 4, 24, and 48 hr after NP injection. Due to the limited amount of blood from each animal, none were used for more than two time points. Blood samples were drawn from four independent mice for each time point. Blood (100 μl) was added to a 96 well clear bottom plate and scanned on the Odyssey NIR fluorescence imaging instrument (LI-COR) using the 700 nm-channel (λexc = 685 nm with λem = 705 nm). The concentration of NP was interpolated from the NP-siScr-Dy677-CTX fluorescence standard curve.
Wang K., Kievit F.M., Chiarelli P.A., Stephen Z.R., Lin G., Silber J.R., Ellenbogen R.G, & Zhang M. (2020). siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model. Advanced functional materials, 31(6), 2007166.
+ Open protocol
+ Expand
3

In Vivo Bioluminescence Imaging of Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were anesthetized with an intraperitoneal injection of 75 mg/kg of sodium pentobarbital (P276000, Toronto Research Chemicals) and transferred to an imaging chamber. Mice were imaged from dorsal or ventral view using Xenogen IVIS Lumina II system equipped with the charge-coupled device (CCD) camera (PerkinElmer, MA). Bioluminescence images were quantified using the Xenogen Corperation Living Image software (PerkinElmer, MA). The total intensity was calculated from a user-defined area of interest covering the whole animal body except the paws. Lower limit of quantification of imaging is approximately 1×108 photons (p).
Zhou C., Cai H., Baruch A., Lewin-Koh N., Yang M., Guo F., Xu D., Deng R., Hazenbos W, & Kamath A.V. (2019). Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging. PLoS ONE, 14(10), e0224096.
+ Open protocol
+ Expand
4

Bioluminescence Imaging of Xenograft Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
BLI was performed using the Xenogen IVIS Lumina II system (Perkin Elmer, Waltham, MA, USA) as detailed previously [27 (link)]. 8 min after intraperitoneal injection of D-Luciferin (150 mg/kg), the animals were imaged, and the same procedure was repeated at the specified time. Regions of interest (ROI) imaging signals were quantified in units of mean photons per second per square centimeter per steradian (p/s/cm2/sr).
Jia X.H., Du Y., Mao D., Wang Z.L., He Z.Q., Qiu J.D., Ma X.B., Shang W.T., Ding D, & Tian J. (2015). Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages. Oncotarget, 6(28), 26018-26028.
+ Open protocol
+ Expand
5

In vivo Bioluminescence Imaging Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the in vivo drug treatment evaluation among 4 groups (10 mice each group), Xenogen IVIS Lumina II system (Perkin Elmer, Waltham, MA, USA) was used to monitor BLI as detailed previously [17 (link)] every 3 days during drug treatment. D-Luciferin was injected i.p. at a dose of 150 mg/kg and after 10 min mice were imaged dynamically during drug treatment. The imaging signal of regions of interest (ROI) was quantified by the mean photons per second per square centimeter per steradian (p/s/cm2/sr).
Li Y., Du Y., Sun T., Xue H., Jin Z, & Tian J. (2018). PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. BMC Cancer, 18, 669.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!